Therapeutic Asset Ratings
7,018 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
FILGRASTIM
Nodular Sclerosis Classical Hodgkin Lymphoma
National Cancer Institute (NCI)
P3
BB
(69)
FILGRASTIM
Chemotherapy-induced Neutropenia
Ankara Etlik City Hospital
P3
BB
(69)
FILGRASTIM
Hodgkin'S Lymphoma, Lymphocytic Depletion
National Cancer Institute (NCI)
P3
BB
(69)
FILGRASTIM
Childhood Mixed Cellularity Hodgkin Lymphoma
National Cancer Institute (NCI)
P3
BB
(69)
FILGRASTIM
Childhood Nodular Sclerosis Hodgkin Lymphoma
National Cancer Institute (NCI)
P3
BB
(69)
FILGRASTIM
Myeloproliferative Neoplasm
City of Hope Medical Center
P3
BB
(69)
FILGRASTIM
HIV Infectious Disease
Fred Hutchinson Cancer Center
P3
BB
(69)
FILGRASTIM
Myelodysplastic Syndrome With Excess Blasts
M.D. Anderson Cancer Center
P3
BB
(69)
Fludarabine
Disease Related To Hematopoietic Stem Cell Transplant
First Affiliated Hospital of Zhejiang University
P3
BB
(69)
Fludarabine
Plasma Cell Neoplasm
Affiliated Hospital to Academy of Military Medical Sciences
P3
BB
(69)
Fludarabine
Prolymphocytic Leukemia
Center for International Blood and Marrow Transplant Research
P3
BB
(69)
Fludarabine
Lymphoblastic Lymphoma
Ohio State University Comprehensive Cancer Center
P3
BB
(69)
Fludarabine
Disease Related To Transplantation
M.D. Anderson Cancer Center
P3
BB
(69)
Fludarabine
Untreated Adult Acute Myeloid Leukemia
City of Hope Medical Center
P3
BB
(69)
FLUDEOXYGLUCOSE
Non-Small Cell Lung Carcinoma
Alliance for Clinical Trials in Oncology
P3
BB
(69)
FLUDROCORTISONE
Congenital Adrenal Hyperplasia
University of Texas Southwestern Medical Center
P3
BB
(69)
FLUOROURACILUM
Liver Metastasis Colon Cancer
Jun Huang
P3
BB
(69)
FLUOROURACILUM
Peritoneum Cancer
City of Hope Medical Center
P3
BB
(69)
Gilteritinib
Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
The First Affiliated Hospital of Soochow University
P3
BB
(69)
Hetrombopag
Thrombocytopenia
Sun Yat-sen University
P3
BB
(69)
HR20013
Chemotherapy-Induced Toxicity
Fujian Shengdi Pharmaceutical Co., Ltd.
P3
BB
(69)
Imatinib
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
The University of Hong Kong
P3
BB
(69)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Colon Carcinoma
IFOM ETS - The AIRC Institute of Molecular Oncology
P3
BB
(69)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Recurrent Colon Carcinoma
IFOM ETS - The AIRC Institute of Molecular Oncology
P3
BB
(69)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Lymphoplasmacytic Lymphoma
Memorial Sloan Kettering Cancer Center
P3
BB
(69)
Showing 701 to 725 of 7,018 assets
Previous
Page 29 of 281
Next